Answers are grounded in this paper and cite their sources.
Tipifarnib demonstrated encouraging efficacy in patients with R/M HNSCC with HRAS mutations for whom limited therapeutic options exist (NCT02383927).
No takes yet. Share an insight, caveat, or question.
Ho et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: